JTL
BBIO icon

Jupiter Topco LLC’s BridgeBio Pharma BBIO Stock Holding History

Jupiter Topco LLC’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05B Buy
+14,110,278
New +$988M 0.43% 43

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Jupiter Topco LLC's BBIO Position: Q2 2026 in Review

Jupiter Topco LLC opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 14,110,278 shares worth $1.05B. The stake represents 0.43% of the portfolio and ranks #43 among its holdings.

439 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Jupiter Topco LLC held 14,110,278 shares of BridgeBio Pharma worth $1.05B as of Q2 2026.
  • BridgeBio Pharma was a new Jupiter Topco LLC position in Q2 2026.
  • BridgeBio Pharma made up 0.43% of Jupiter Topco LLC's portfolio in Q2 2026, its #43 holding.
  • 439 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Jupiter Topco LLC's 13F filing for Q2 2026, filed 14 Aug 2026.